Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥19.2bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥32.4bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥13.7bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥3.3bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥3.2bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax¥6.9bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥2.2bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥2.2bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥136.1bnat 2024-09-30Cons.Assets IFRS
Total assets¥122.5bnat 2024-03-31Cons.Assets IFRS
Total assets¥100.0bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥63.7bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥51.8bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥72.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥70.7bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥68.7bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥72.1bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥70.6bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥68.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥27.5bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.5bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥21.5bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥10.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥17m2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥2.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥4.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥24.9bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥3.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥6.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥16.6bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥341m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥33.512024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥71.762023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.22023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥33.182024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥69.952023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥40.532023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio52.9%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio57.6%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.6%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 35
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥21m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥21m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥379m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2024-04-01 → 2024-09-30¥649m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2024-04-01 → 2024-09-30¥649m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2024-04-01 → 2024-09-30¥116m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2024-04-01 → 2024-09-30¥15.5bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2024-04-01 → 2024-09-30¥15.5bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥21m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2024-04-01 → 2024-09-30¥3.8bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2024-04-01 → 2024-09-30¥3.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2024-04-01 → 2024-09-30¥3.1bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2024-04-01 → 2024-09-30¥1.1bn
—segment totalrevenue2024-04-01 → 2024-09-30¥19.2bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥19.2bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥21m
—segment totalsegment profit2024-04-01 → 2024-09-30¥5.0bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥338m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥50m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-09-30¥133m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥38m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥1.0bn
—segment totalrevenue2023-04-01 → 2023-09-30¥13.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥13.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥89m
—segment totalsegment profit2023-04-01 → 2023-09-30¥3.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 769
ItemContextValueUnit
Issuance of share acquisition rights ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-JPY
Issuance of share acquisition rights ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Issuance of share acquisition rights ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-JPY
Issuance of share acquisition rights ss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember6000000JPY
Exercise of share acquisition rights ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember1099000000JPY
Exercise of share acquisition rights ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember1099000000JPY
Exercise of share acquisition rights ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-JPY
Exercise of share acquisition rights ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Exercise of share acquisition rights ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-JPY
Exercise of share acquisition rights ss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember-7000000JPY
Forfeiture of share acquisition rights ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember-JPY
Forfeiture of share acquisition rights ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember0JPY
Forfeiture of share acquisition rights ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-JPY
Forfeiture of share acquisition rights ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Forfeiture of share acquisition rights ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-JPY
Forfeiture of share acquisition rights ss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember-0JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember-JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-0JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember-JPY
Dividends ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember-JPY
Dividends ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-JPY
Dividends ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-JPY
Dividends ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Dividends ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-JPY
Dividends ss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember-JPY
Increase decrease by business combination ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember-JPY
Increase decrease by business combination ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-13000000JPY
Increase decrease by business combination ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-JPY
Increase decrease by business combination ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Increase decrease by business combination ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-JPY
Increase decrease by business combination ss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember-JPY
Transfer to retained earnings ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember-JPY
Transfer to retained earnings ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember-JPY
Transfer to retained earnings ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember-JPY
Transfer to retained earnings ss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Transfer to retained earnings ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-5000000JPY
Transfer to retained earnings ss IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember-JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember1099000000JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember1086000000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember-0JPY
Total transactions with owners IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-JPY
Total transactions with owners IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember-5000000JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareAcquisitionRightsIFRSMember-1000000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember25094000000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember28298000000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-2000000JPY
Equity IFRSPrior1QuarterInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-5000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass